Houdini Bio emerges from stealth with €1.7 million to tackle DNA silencing in gene therapies

British biotech startup Houdini Bio has exited stealth mode today, announcing approximately €1.7 million (£1.5 million) in pre-seed funding. The capital will be used to validate its DNA sequence design infrastructure platform, engineered to overcome the biological barriers limiting genetic medicines.

The round was led by SCVC (the venture arm of Science Creates), with participation from Deep Science Ventures and the University of Cambridge (Cambridge Enterprise VC). The combined funding enabled Houdini Bio to rapidly validate its technology and achieve projected technical milestones in a third of the predicted time.

“The industry has made incredible strides, proving genetic medicines can cure previously untreatable diseases, but cellular machinery still rejects these therapies, limiting long term effectiveness and forcing costly, unsafe doses,” said Jonathan Cohen-Gold, CEO and co-founder of Houdini Bio. “Our platform introduces a vital shift from trial-and-error screening to repeatable, engineering-driven DNA design. By discovering the molecular rules which allow sequences to escape HUSH, we can rewrite therapeutic DNA to clear cellular checkpoints.”

Houdini Bio’s platform combines machine learning with an understanding of cellular defense mechanisms, specifically the Human Silencing Hub (HUSH) complex. This allows the company to re-engineer therapeutic DNA, giving it a genetic camouflage that makes it invisible to the cell's defenses. The company claims the platform can boost gene expression output by more than 10-fold compared to current state-of-the-art methods.

Founded in 2025, Houdini Bio plans to expand its team and scale co-development partnerships with pharma companies and other innovators to integrate anti-silencing technology into next-generation drug pipelines.